TRAINING GRANT IN CLINICAL PHARMACOLOGY
Principal Investigator: R Weinshilboum
Affiliation: Mayo Clinic
Abstract: This proposal is a request for continued funding of the NIH-sponsored Clinical Pharmacology Fellowship Training Program at the Mayo Medical School-Mayo Clinic. Clinical Pharmacology is the study of the interaction between therapeutic agents and humans. However, in the context of the ongoing "Genomics Proteomics Revolution" in biomedical science, Clinical Pharmacology represents an important interface between basic molecular genetic, Genomic and proteomic science and rational therapeutics. Bridge disciplines such as Clinical Pharmacology are uniquely poised to take advantage of the revolution in biomedicine to apply this new scientific information at the translational interface in order to provide an understanding of the molecular basis for human response to drug therapy. However, the ability to take advantage of this unique opportunity will require the training of a new generation of Clinical Pharmacologists who are thoroughly grounded in basic molecular science and who are able to apply that science to study the interaction between patients and drugs. At this point in the Genomics-Proteomics Revolution, large comprehensive, integrated academic medical centers like the Mayo Clinic represent ideal locations for the training of this new generation of Clinical Pharmacologists. Mayo is positioned to accept this challenge because its basic science and clinical research programs are highly integrated, because it has a long history of contribution to the discipline of Clinical Pharmacology and because the Mayo Clinical Pharmacology Training Program has already had a decade of experience in successfully recruiting and training academic physicians who wish to apply biological science to Clinical Pharmacology. Fellowship Training that will emphasize a strong laboratory-based scientific experience, exposure to clinical science and highly structured and accountable mentorship is at the heart of the Mayo Clinical Pharmacology Fellowship Training Program described in this proposal.
Funding Period: 1998-07-01 - 2008-06-30
more information: NIH RePORT
- Identification of Th0 cells responding to measles virusRawleigh C Howe
Mayo Vaccine Research Group, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Hum Immunol 66:104-15. 2005....
- Identification of HLA-DRB1-bound self-peptides following measles virus infectionInna G Ovsyannikova
Mayo Vaccine Research Group, 611C Guggenheim Building, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
J Immunol Methods 297:153-67. 2005..This provides further knowledge of the changes in peptide expression after viral infection and provides a powerful tool for identifying HLA-presented host and viral epitopes in the context of class II HLA molecules...
- Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockadeB W Wilkins
Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Clin Pharmacol Ther 83:692-701. 2008..05) and baroreflex changes in MSNA (P<0.01). We conclude that the GLY-DEX alternative drug strategy can be used as a reasonable alternative to pharmacologic ganglionic blockade to examine autonomic cardiovascular control...
- K(ATP) channel pharmacogenomics: from bench to bedsideS Sattiraju
Marriott Heart Disease Research Program, Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Clin Pharmacol Ther 83:354-7. 2008..There is an increased recognition that genetic variability of the K(ATP) channel impacts therapeutic decision-making in human disease...
- Aging is associated with reduced prostacyclin-mediated dilation in the human forearmWayne T Nicholson
Department of Anesthesiology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Hypertension 53:973-8. 2009..Our data suggest that the reduced dilator effects of PGI(2) in older individuals are attributable to a reduction in the contribution of endothelial-derived NO versus alterations in the direct effects of PGI(2) on vascular smooth muscle...
- Sarcolemmal ATP-sensitive K(+) channels control energy expenditure determining body weightAlexey E Alekseev
Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Cell Metab 11:58-69. 2010....